Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany

European Journal of Neurology

Volumn 17, Issue 9, 2010, Pages 1156-1163

  Winter, Y ^a   Balzer Geldsetzer, M ^a   Spottke, A ^b   Reese, J P ^a   Baum, E ^a   Klotsche, J ^c   Rieke, J ^d   Simonow, A ^e   Eggert, K ^a   Oertel, W H ^a   Dodel, R ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d Neurological Practice   (Germany)

^e Neurological Practice ^*  (Germany)

Author keywords

cost; cost of illness; Parkinson's disease; resource utilization; unified Parkinson's disease rating scale

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; CARDIOVASCULAR AGENT; GASTROINTESTINAL AGENT; NEUROLEPTIC AGENT; NOOTROPIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG COST; DYSKINESIA; FEMALE; GERMANY; HEALTH INSURANCE; HEALTH PROGRAM; HOME CARE; HOSPITAL PATIENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NURSING HOME; PARKINSON DISEASE; PRIORITY JOURNAL; SOCIOECONOMICS; UNIFIED PARKINSON DISEASE RATING SCALE;

AGE FACTORS; AGED; ANTIPARKINSON AGENTS; COST OF ILLNESS; COST SAVINGS; DEPRESSIVE DISORDER; DYSKINESIAS; FEMALE; GERMANY; HEALTH CARE COSTS; HEALTH EXPENDITURES; HOME CARE SERVICES; HUMANS; INPATIENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; SOCIOECONOMIC FACTORS;

EID: 77955810459     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.02984.x     Document Type: Article

References (36)

1. Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 2003 18 : 1139 1145.
2. Whetten-Goldstein K, Sloan F, Kulas E, et al. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997 45 : 844 849.
3. LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziegler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999 16 : 59 69.
4. Muller T, Voss B, Hellwig K, Josef Stein F, Schulte T, Przuntek H. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic. CNS Drugs 2004 18 : 105 111. (Pubitemid 38293595)
5. Keller S, Kessler T, Meuser T, Fogel W, Bremen D, Jost WH. Analysis of direct costs in therapy of Parkinson disease. Nervenarzt 2003 74 : 1105 1109.
6. Spottke AE, Reuter M, Machat O, et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005 23 : 817 836.
7. Keranen T, Kaakkola S, Sotaniemi K. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003 9 : 163 168.
8. Hagell P, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 2002 17 : 1213 1220.
9. Haycock J. Idiopathic Parkinson's disease: the burden of illness [Thesis].
10. Noyes K, Liu H, Li Y, Holloway R, Dick AW. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. Mov Disord 2006 21 : 362 372.
11. Ehret R, Balzer-Geldsetzer M, Reese JP, et al. [Direct costs for Parkinson's treatment in private neurology practices in Berlin]. Nervenarzt 2009 80 : 452 458.
12. Winter Y, von Campenhausen S, Brozova H, et al. Costs of illness of Parkinson's disease in Eastern Europe: a Czech cohort study. Parkinsonism Relat Disord 2010 16 : 51 56.
13. Winter Y, von Campenhausen S, Popov G, et al. Costs of Illness in a Russian cohort of Patients with Parkinson's disease. Pharmacoeconomics 2009 27 : 571 584.
14. von Campenhausen S, Winter Y, Gasser J, et al. Cost of illness and health services patterns in Morbus Parkinson in Austria. Wien Klin Wochenschr 2009 121 : 574 582.
15. Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson's disease: an estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998 14 : 299 312.
16. Rubenstein LM, Chrischilles EA, Voelker MD. The impact of Parkinson's disease on health status, health expenditures, and productivity: estimates from the National Medical Expenditure Survey. Pharmacoeconomics 1997 12 : 486 498.
17. Eggert KM, Reese JP, Oertel WH, Dodel R. Cost effectiveness of pharmacotherapies in early Parkinson's disease. CNS Drugs 2008 22 : 841 860.
18. Gibb WRG. Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgrad Med J 1988 64 : 345 512.
19. Beck A, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Ger Psychiatry 1961 4 : 561 567.
20. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 12 : 189 198.
21. Busse R, Riesberg A. Health care systems in transition: Germany.
22. The Federal Statistical Office Germany. http://www.destatis.de (accessed 20052009).
23. The Federation of German Pharmaceutical Industry. Rote Liste.
24. The Federal Ministry for Health and Social Secure. http://www.bmg.bund.de (accessed 15052009).
25. Deutscher Ärzteverlag. Einheitlicher Bewertungsmasstab.
26. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000 19 : 3219 3236.
27. Efron B, Tibshirani RJ. An Introduction to the Bootstrap.
28. Harrell FE. Regression modeling strategies.
29. Wullner U, Schmitz-Hubsch T, Antony G, et al. Autonomic dysfunction in 3414 Parkinson's disease patients enrolled in the German Network on Parkinson's disease (KNP e.V.): the effect of ageing. Eur J Neurol 2007 14 : 1405 1408.
30. Singer E. Social costs of Parkinson's disease. J Chronic Dis 1973 26 : 243 254.
31. Berger K, Breteler MM, Helmer C, et al. Prognosis with Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000 54 : S24 S27.
32. MacMahon DG, Findley L, Holmes J, Pugner K. The true economic impact of Parkinson's disease: a research survey in the U.K. Mov Disord 2000 15 : 178 179.
33. Simon GE, Khandker RK, Ichikawa L, Operskalski BH. Recovery from depression predicts lower health services costs. J Clin Psychiatry 2006 67 : 1226 1231.
34. Visser M, van Rooden SM, Verbaan D, Marinus J, Stiggelbout AM, van Hilten JJ. A comprehensive model of health-related quality of life in Parkinson's disease. J Neurol 2008 255 : 1580 1587.
35. Santangelo G, Vitale C, Trojano L, et al. Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. J Neurol 2009 256 : 632 638.
36. Schöffski O, Claes C. Die standardisierung der methodik: guidelines. In : Schöffski O, Graf von der Schulenburg J-M, eds. Gesundheitsö konomische Evaluationen.